U.S. markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.9500+0.2100 (+5.61%)
At close: 04:00PM EST
3.9100 -0.04 (-1.01%)
After hours: 07:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close3.7400
Bid3.9100 x 2200
Ask4.0000 x 1000
Day's Range3.6700 - 3.9500
52 Week Range3.6700 - 10.0500
Avg. Volume1,244,734
Market Cap257.734M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CTMX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CytomX Therapeutics, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Insider Monkey

    10 Small-Cap Stocks to Buy According to Billionaire Steve Cohen

    In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […]

  • GlobeNewswire

    CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.

  • TipRanks

    Is CytomX Stock a Buy Following Disappointing Cancer Therapy Results? Analyst Weighs In

    An investment in a biotech company is not without risk, and last week, CytomX Therapeutics (CTMX) investors got a painful reminder of the consequences should clinical testing not go as hoped for. Shares dropped by 40% in a single session after the data from the Phase 2 trial of experimental cancer therapy CX-2029 failed to impress. The study was assessing the drug as a treatment for patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcino